Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03742102 · ClinicalTrials.gov registry record · Phase 1

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

A Phase 1 study of Triple Negative Breast Neoplasms, sponsored by AstraZeneca.

Active
Registry status
Phase 1
Development phase
243
Enrollment target
20
Study locations

NCT03742102 is a Phase 1 study of Triple Negative Breast Neoplasms that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 243 participants, below the 639-participant average among 10 other Triple Negative Breast Neoplasms trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03742102, a Phase 1 study of Triple Negative Breast Neoplasms, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
243 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer

Conditions Studied

Triple Negative Breast Neoplasms

Interventions

  • DRUG Paclitaxel
  • DRUG Trastuzumab deruxtecan
  • DRUG Capivasertib
  • DRUG Durvalumab
  • DRUG Oleclumab

Study Locations (20)

Other

  • Research Site - Gdansk
  • Research Site - Krakow
  • Research Site - Lublin
  • Research Site - Opole
  • Research Site - Rzeszów
  • Research Site - Warsaw
  • Research Site - Warsaw
  • Research Site - Seoul

Massachusetts

  • Research Site - Boston
  • Research Site - Boston

Quebec

  • Research Site - Greenfield Park
  • Research Site - Montreal

Arizona

  • Research Site - Tucson

Maryland

  • Research Site - Columbia

Michigan

  • Research Site - Grand Rapids

Missouri

  • Research Site - St Louis

Texas

  • Research Site - Dallas

Trial Details

FieldValue
Enrollment Target 243 participants
Start Date 2018-12-21
Est. Completion 2027-02-26
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03742102

The ClinicalTrials.gov registry entry for NCT03742102 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 639-participant average among 10 other Triple Negative Breast Neoplasms trials with a reported enrollment target (62% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Triple Negative Breast Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Paclitaxel is the first listed.

NCT03742102 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Massachusetts, Quebec.

Frequently Asked Questions

What is clinical trial NCT03742102 about?

NCT03742102 is a clinical study titled "A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer". This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer

What is the current status of trial NCT03742102?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 243 participants. The study started on 2018-12-21. Estimated completion is 2027-02-26.

What conditions does trial NCT03742102 study?

This clinical trial studies the following conditions: Triple Negative Breast Neoplasms.

What interventions are being tested in trial NCT03742102?

The interventions under investigation include: Paclitaxel (DRUG), Trastuzumab deruxtecan (DRUG), Capivasertib (DRUG), Durvalumab (DRUG), Oleclumab (DRUG).

Who is sponsoring clinical trial NCT03742102?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03742102 being conducted?

This trial has 20 study locations across Arizona, Maryland, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Triple Negative Breast Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Triple Negative Breast Neoplasms

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.